Metraipolis › archive › dc_ef3b4381eb27

Provider anticipation and experience of patient reaction when deprescribing guideline discordant inhaled corticosteroids — Europe PMC PMID:32941462

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/32941462
DOI
10.1371/journal.pone.0238511
License (as archived)
CC0-1.0
Archived
2026-11-07T11:42:53.710Z
SHA-256 of the archived text
bd7a60b6f381b4d75fd138866174c44f88000ac62d3076250b843aa376227ad2
Stable URL of this page
https://metraipolis.com/documento/dc_ef3b4381eb27

How to cite

Provider anticipation and experience of patient reaction when deprescribing guideline discordant inhaled corticosteroids — Europe PMC PMID:32941462 — Europe PMC (en), https://europepmc.org/article/MED/32941462 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_ef3b4381eb27 (Metraipolis archive dc_ef3b4381eb27, sha256 bd7a60b6f381b4d75fd138866174c44f88000ac62d3076250b843aa376227ad2)
BibTeX
@misc{dcef3b4381eb27,
  title = {Provider anticipation and experience of patient reaction when deprescribing guideline discordant inhaled corticosteroids — Europe PMC PMID:32941462},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/32941462},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_ef3b4381eb27; sha256 bd7a60b6f381b4d75fd138866174c44f88000ac62d3076250b843aa376227ad2},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/32941462. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Introduction: Despite evidence of possible patient harm and substantial costs, medication overuse is persistent. Patient reaction is one potential barrier to deprescribing, but little research has assessed this in specific instances of medication discontinuation. We sought to understand Veteran and provider experience when de-implementing guideline-discordant use of inhaled corticosteroids (ICS) in those with mild-to-moderate chronic obstructive pulmonary disease (COPD). Methods: We conducted a mixed-methods analysis in a provider-randomized quality improvement project testing a proactive electronic-consultation from pulmonologists recommending ICS discontinuation when appropriate. PCPs at two Veterans Health Administration healthcare systems were included. We completed interviews with 16 unexposed providers and 6 intervention-exposed providers. We interviewed 9 patients within 3 months after their PCP proposed ICS discontinuation. We conducted inductive and deductive content analysis of qualitative data to explore an emergent theme of patient reaction. Forty-eight PCPs returned surveys (24 exposed and 24 unexposed, response rate: 35%). Results: The unexposed providers anticipated their patients might resist ICS discontinuation because it seems counterintuitive to stop something that is working, patient's fear of worsening symptoms, or if the prescription was initiated by another provider. Intervention-exposed providers reported similar experiences in post-intervention interviews. Unexposed providers anticipated that patients may accept ICS discontinuation, citing tactical use of patient-centered care strategies. This was echoed by intervention-exposed providers who had successfully discontinued an ICS. Veterans reported acceding to their providers out of trust or deference to their advanced training, even after describing an ICS as a 'security blanket'. Our survey findings supported the subthemes from our interviews. Among providers who proposed discontinuation of an ICS, 76% reported that they were able to discontinue it or switch to another more appropriate medication. Conclusions: While PCPs anticipated that patients would resist discontinuing an ICS, interviews with patient and intervention-exposed PCPs along with surveys suggest that patients were receptive to this change.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2020 (prima pubblicazione 2020-09-17).
Identificativi: PMID 32941462 · PMCID PMC7498097 · DOI 10.1371/journal.pone.0238511.
Descrittori MeSH principali: Deprescriptions.
Pagina: https://europepmc.org/article/MED/32941462 — https://doi.org/10.1371/journal.pone.0238511. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-07T11:38:21.093Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.